Skip to main content
    E

    Evolus Inc (EOLS)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $6.63
    -0.33 (-4.74%)

    Market Cap: $460.67M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Evolus Inc (EOLS) Earnings: Report Dates and Results

    Updated Nov 4, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Evolus (EOLS) is expected to report earnings on Mar 1, 2027. In the quarter ended Sep 30, 2026, Evolus reported EPS of -$0.16, below the -$0.14 estimate. It beat the EPS estimate in 2 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    39%(14/36)
    Avg Surprise
    -12.42%

    Upcoming Estimates

    Reports Mar 1, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.06
    Range$0.00 - $0.15
    8 analysts
    Revenue Consensus
    $101.12M
    Range$96.24M - $105.61M
    8 analysts
    Reports May 3, 2027 (est.)Period ending Mar 31, 2027
    EPS ConsensusN/A
    RangeN/A
    1 analysts
    EPS Revisions
    1
    0
    30d
    Revenue Consensus
    $87.89M
    Range$83.77M - $92.00M
    2 analysts

    Next Report

    EOLS has an expected report date of Mar 1, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 500.0% above the $0.01 reported for the quarter ended Dec 31, 2025.

    EOLS Earnings Call

    The latest EOLS earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 36 quarters below that had an estimate, EOLS beat 14, missed 18 and matched 4. Revenue for the quarter ended Sep 30, 2026 was $77.95M, up 13.0% from $68.97M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.16-$0.14N/A-14.29%MissN/A42 up, 1 downNov 4, 2026$77.95M
    Jun 30, 2026-$0.09-$0.09N/A0.00%In lineN/A50 up, 1 downAug 5, 2026$84.08M
    Mar 31, 2026-$0.05-$0.12-$0.14 - -$0.08+58.33%BeatN/A42 up, 0 downMay 4, 2026$73.14M
    Dec 31, 2025$0.01$0.04$0.02 - $0.05-64.61%Miss-5.0%30 up, 0 downMar 3, 2026$90.30M
    Sep 30, 2025-$0.20-$0.26N/A+23.08%BeatN/A30 up, 2 downNov 5, 2025$68.97M
    Jun 30, 2025-$0.26-$0.09-$0.12 - -$0.05-188.89%MissN/A30 up, 0 downAug 5, 2025$69.39M
    Mar 31, 2025-$0.17-$0.14-$0.19 - -$0.09-21.43%MissN/A30 up, 0 downMay 7, 2025$68.52M
    Dec 31, 2024$0.01$0.02$0.02 - $0.03-37.67%MissN/A31 up, 0 downMar 4, 2025$78.95M
    Sep 30, 2024-$0.18-$0.11-$0.14 - -$0.03-63.64%MissN/A40 up, 0 downNov 6, 2024$61.09M
    Jun 30, 2024-$0.06-$0.06-$0.11 - -$0.030.00%In lineN/A40 up, 0 downJul 31, 2024$66.91M
    Mar 31, 2024-$0.11-$0.08-$0.20 - -$0.05-37.50%MissN/A40 up, 0 downMay 7, 2024$59.33M
    Dec 31, 2023-$0.12-$0.07-$0.09 - -$0.05-71.43%MissN/A40 up, 0 downMar 7, 2024$61.00M
    Sep 30, 2023-$0.18-$0.18-$0.24 - -$0.120.00%In lineN/A50 up, 0 downNov 7, 2023$50.02M
    Jun 30, 2023-$0.22-$0.20-$0.24 - -$0.15-10.00%MissN/A52 up, 0 downAug 2, 2023$49.35M
    Mar 31, 2023-$0.17-$0.16-$0.26 - -$0.09-6.25%MissN/A60 up, 0 downMay 9, 2023$41.72M
    Dec 31, 2022-$0.14-$0.15-$0.19 - -$0.07+6.67%BeatN/A50 up, 0 downMar 8, 2023$43.65M
    Sep 30, 2022-$0.29-$0.29-$0.34 - -$0.230.00%In lineN/A50 up, 1 downNov 8, 2022$33.90M
    Jun 30, 2022-$0.30-$0.24-$0.30 - -$0.21-25.00%MissN/A50 up, 0 downAug 2, 2022$37.16M
    Mar 31, 2022-$0.24-$0.33-$0.55 - -$0.23+27.27%BeatN/A51 up, 0 downMay 10, 2022$33.91M
    Dec 31, 2021-$0.24-$0.21-$0.21 - -$0.17-14.29%MissN/A5N/AMar 3, 2022$34.66M
    Sep 30, 2021-$0.28-$0.27-$0.51 - -$0.10-3.70%MissN/A5N/ANov 2, 2021$26.68M
    Jun 30, 2021-$0.19-$0.25-$0.30 - -$0.16+24.00%BeatN/A5N/AAug 4, 2021$26.10M
    Mar 31, 2021-$0.20-$0.43-$0.53 - -$0.19+53.49%BeatN/A5N/AMay 12, 2021$12.24M
    Dec 31, 2020-$0.44-$0.22-$0.27 - -$0.14-100.00%MissN/A6N/AMar 24, 2021$20.58M
    Sep 30, 2020-$0.33-$0.37-$0.45 - -$0.26+10.81%BeatN/A6N/AOct 29, 2020$17.66M
    Jun 30, 2020-$0.43-$0.69-$0.77 - -$0.61+37.68%BeatN/A6N/AAug 10, 2020$7.81M
    Mar 31, 2020-$0.75-$0.62-$0.77 - -$0.45-20.97%MissN/A7N/AMay 11, 2020$10.50M
    Dec 31, 2019-$0.51-$0.68-$0.97 - -$0.61+25.00%BeatN/A6N/AFeb 25, 2020$19.45M
    Sep 30, 2019-$0.96-$1.14-$1.23 - -$0.84+15.79%BeatN/A7N/ANov 4, 2019$13.17M
    Jun 30, 2019-$1.32-$0.84-$1.12 - -$0.27-57.14%MissN/A7N/AAug 12, 2019$2.31M
    Mar 31, 2019-$0.82-$0.62-$1.27 - -$0.61-32.26%MissN/A5N/AApr 30, 2019N/A
    Dec 31, 2018-$0.46-$0.55-$0.67 - -$0.40+16.36%BeatN/A6N/AMar 18, 2019N/A
    Sep 30, 2018-$0.38-$0.42-$0.51 - -$0.28+9.52%BeatN/A4N/ANov 5, 2018N/A
    Jun 30, 2018-$0.35-$0.32-$0.37 - -$0.18-9.38%MissN/A4N/AAug 2, 2018N/A
    Mar 31, 2018-$0.30-$0.36-$0.36 - -$0.15+16.67%BeatN/A4N/AMay 10, 2018N/A
    Dec 31, 2017-$0.28-$0.30N/A+6.67%BeatN/AN/AN/AFeb 9, 2018N/A
    Sep 30, 2017-$0.26N/AN/AN/AN/AN/AN/AN/ANov 29, 2017N/A
    Jun 30, 2017-$0.27N/AN/AN/AN/AN/AN/AN/AAug 28, 2017N/A
    Mar 31, 2017-$0.17N/AN/AN/AN/AN/AN/AN/AJun 29, 2017N/A
    Last 39 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$0.62, after -$0.34 the year before. It was -$0.98 for the year ended Dec 31, 2017, the oldest of the 9 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$0.62N/A
    Dec 31, 2024-$0.34N/A
    Dec 31, 2023-$0.69N/A
    Dec 31, 2022-$0.97N/A
    Dec 31, 2021-$0.91N/A
    Dec 31, 2020-$1.95N/A
    Dec 31, 2019-$3.61N/A
    Dec 31, 2018-$1.49N/A
    Dec 31, 2017-$0.98N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,000 words across 10 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20265,00310
    2026Q2Jun 30, 20265,74711
    2026Q1Mar 31, 20265,78112
    2025Q4Dec 31, 20257,15312
    2025Q3Sep 30, 20256,24312
    2025Q2Jun 30, 20256,26011
    2025Q1Mar 31, 20255,73811
    2024Q4Dec 31, 20247,07911

    2026Q3 Earnings Call

    Opening remarks

    Nareg Sagherian Vice President and Head of Global Investor Relations and Corporate Communications Thank you, operator, and welcome to everyone joining us on today's call to review Evolus' third quarter financial results. Our third quarter press release is now available on the Investor Relations section of our website at evolus.com. Joining me on today's call are David Moatazedi, President and Chief Executive Officer; Rui Avelar, Chief Medical Officer and Head of R&D; and Tatjana Mitchell, Chief Financial Officer. Today's call will include forward-looking statements. Actual results may differ materially due to risks and uncertainties outlined in our earnings press release and SEC filings. These forward-looking statements are based on current assumptions, and we undertake no obligation to update them. Additionally, we will discuss certain non-GAAP financial measures. These measures should be considered in addition to, and not as a substitute for, our GAAP results. A reconciliation of GAAP to non-GAAP measures is included in today's earnings release. As a reminder, our earnings release and SEC filings are available on the SEC's website and on our Investor Relations website. Following the conclusion of today's call, a replay will be available on our website at investors.evolus.com. With that, I'll turn the call over to our CEO, David Moatazedi.

    David Moatazedi President and Chief Executive Officer Thank you, Nareg, and good afternoon, everyone. I'm pleased to report our fourth consecutive quarter of positive adjusted EBITDA and continued above-market growth while continuing to expand our portfolio with differentiated assets. These results reflect our deliberate strategy to build on the strength of our established brand while creating additional opportunities for long-term growth. Evolus is now a more diversified global performance beauty company with a growing international commercial portfolio, an expanding pipeline, and improving financial performance. At the beginning of the year, we outlined three priorities to guide our progress: commercial execution, financial discipline, and pipeline expansion. Let me update you on each priority. On commercial execution, global toxin revenue grew approximately 11%, both in the third quarter and year to date, while our newly launched HA business grew nearly 40% in the quarter and more than 50% year to date. On financial discipline, we delivered our fourth consecutive quarter of positive adjusted EBITDA while continuing to invest in our commercial priorities and portfolio development. Importantly, through the first nine months, revenue grew 14%, while we maintained nearly flat non-GAAP operating expenses, demonstrating the outstanding leverage of our portfolio of products. On pipeline expansion, we've added skin quality as a third pillar within our U.S. facial injectable pipeline through our partnership with IBSA for Profhilo. We also recently announced an early-stage option agreement in procedure-based injectable hair growth, which adds a longer-term opportunity in a complementary aesthetic category. Turning to the quarter.

    Frequently Asked Questions About EOLS

    When is Evolus's next earnings date?

    Evolus's next earnings report is expected for Mar 1, 2027.

    Did EOLS beat earnings estimates last quarter?

    No. Evolus reported EPS of -$0.16 for the quarter ended Sep 30, 2026, below the -$0.14 estimate by 14.29%.

    What EPS do analysts expect from EOLS next quarter?

    The consensus EPS estimate for Evolus for the quarter ending Dec 31, 2026 is $0.06 from 8 analysts, with estimates from $0.00 to $0.15.

    How often does EOLS beat earnings estimates?

    Evolus beat the EPS estimate in 2 of the last 8 quarters, with an average surprise of -30.68%.